Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.
Simple Summary: Targeted treatments for advanced gastric cancer have been shown to improve survival when added to conventional chemotherapy. A claudin18.2-targeted drug, zolbetuximab, and two immune checkpoint inhibitors, nivolumab and pembrolizumab, are now approved as initial therapies for advance...
| Publicado en: | Current Oncology Vol. 32; no. 11; pp. 648 - 660 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |